| P50 | author | Danit Sofer | Q105532187 |
| | Lester M Shulman | Q56816729 |
| | Ella Mendelson | Q60299300 |
| P2093 | author name string | Lucia Fiore | |
| | Francis Delpeyroux | |
| | Jean Balanant | |
| | Yossi Manor | |
| | Anna Laura Salvati | |
| P2860 | cites work | Effect of chloro-, cyano-, and amidino-substituted flavanoids on enterovirus infection in vitro | Q71557211 |
| | Oral poliovaccine: will it help eradicate polio or cause the next epidemic? | Q79805822 |
| | Immunisation against poliomyelitis: moving forward | Q81118643 |
| | Infectious diseases. Report concludes polio drugs are needed--after disease is eradicated | Q82858519 |
| | Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage | Q84253151 |
| | Implications of a circulating vaccine-derived poliovirus in Nigeria. | Q50602639 |
| | Polio eradication. Looking for a little luck. | Q50611686 |
| | Laboratory surveillance for wild poliovirus and vaccine-derived poliovirus, 2000-2001. | Q53314670 |
| | Type 2 polio still in our midst. | Q64900214 |
| | Problems with oral poliovaccine in India | Q69408261 |
| | Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates | Q70461518 |
| | VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION * | Q22255613 |
| | The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools | Q24248165 |
| | Circulating vaccine-derived polioviruses: current state of knowledge | Q24655387 |
| | Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range | Q24655520 |
| | Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes | Q27742037 |
| | Activities and mechanisms of action of halogen-substituted flavanoids against poliovirus type 2 infection in vitro | Q28330392 |
| | Effect of isoflavans and isoflavenes on the infection of Frp/3 cells by hepatitis A virus | Q28343018 |
| | WWW-query: an on-line retrieval system for biological sequence banks | Q29617307 |
| | Neurovirulent vaccine-derived polioviruses in sewage from highly immune populations | Q33267329 |
| | Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority. | Q33960667 |
| | Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. | Q33969974 |
| | Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient | Q34045658 |
| | Identification of the pocket factors in a picornavirus | Q34198481 |
| | Update on vaccine-derived polioviruses--worldwide, January 2006-August 2007. | Q34583358 |
| | Advanced environmental surveillance and molecular analyses indicate separate importations rather than endemic circulation of wild type 1 poliovirus in Gaza district in 2002. | Q36136750 |
| | Potential use of antiviral agents in polio eradication | Q36944919 |
| | Retrospective Analysis of a Local Cessation of Vaccination against Poliomyelitis: a Possible Scenario for the Future | Q37060273 |
| | A case for developing antiviral drugs against polio | Q37177805 |
| | Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. | Q37423069 |
| | Future of polio vaccines | Q37450453 |
| | Antiviral activity of substituted homoisoflavonoids on enteroviruses. | Q40239263 |
| | Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus | Q40882626 |
| | Synthesis and anti-rhinovirus properties of fluoro-substituted flavonoids | Q43553651 |
| | Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. | Q44401277 |
| | Polio eradication in India: some observations | Q44613483 |
| | Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. | Q44890455 |
| | Update on vaccine-derived polioviruses--worldwide, January 2008-June 2009. | Q45157670 |
| | Surge in polio spreads alarm in northern Nigeria. Rumours about vaccine safety in Muslim-run states threaten WHO's eradication programme | Q46240409 |
| | Getting Polio Eradication Back on Track in Nigeria | Q46248804 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virulence | Q1460232 |
| | sewage | Q10966166 |
| | Poliovirus | Q70923324 |
| P304 | page(s) | e18360 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Antiviral activity of 3(2H)- and 6-chloro-3(2H)-isoflavenes against highly diverged, neurovirulent vaccine-derived, type2 poliovirus sewage isolates | |
| P478 | volume | 6 | |